Drug Trial Radar · NCT07111520
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Nov 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- MediLink Therapeutics (Suzhou) Co., Ltd.
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available). The main goals of this study are: 1. To find the best dose levels (DLs) for the combination of BNT326 and pumitamig. 2. To look at how well participants with advanced NSCLC tolerate the combination therapy (for example, which side effects participants experience and how severe they are). 3. To look at how well the combination therapy works to shrink the tumor in participants with advanced NSCLC.
Conditions
- Non-small Cell Lung Cancer
Interventions
BNT326Drug
intravenous (IV) infusion
PumitamigDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participantTime frame: 21 days starting on Day 1 of Cycle 1
- Part 1 and Part 2a - Occurrence of treatment emergent adverse events (TEAEs), treatment-related adverse events (TRAE), treatment emergent serious adverse events (TESAE), treatment-related serious adverse events (TRSAE)Time frame: from the first dose of investigational medicinal product (IMP) up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
- Part 1 and Part 2a - Occurrence of dose interruption, reduction, and discontinuation due to TEAEsTime frame: from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
- Part 2a and Part 2b - Objective response rate (ORR)Time frame: from the time of initiation of the first dose of IMP to approximately 36 months
Locations
87 sites in 10 countries. Site status is shown where the registry gives one.
UCLA Hematology Oncology - Main Site
Los Angeles, California · Recruiting
Stanford Cancer Institute
Stanford, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Georgetown University - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Moffit Cancer Center
Tampa, Florida · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
Cleveland, Ohio · Recruiting
University of Texas M. D. Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Cancer Research SA
Adelaide, Australia · Recruiting
St George Private Hospital
Kogarah, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, Australia · Recruiting
Mater
South Brisbane, Australia · Recruiting
John Flynn Private Hospital
Tugun, Australia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Affiliated Hospital of Hebei University
Baoding, China · Recruiting
Beijing GoBroad Hospital
Beijing, China · Recruiting
The First Hospital of Jilin University
Changchun, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, China · Recruiting
The First Affiliated Hospital School of Clinical Medicine of Guangdong Pharmaceutical University
Guangzhou, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China · Recruiting
Anhui Chest Hospital
Hefei, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, China · Recruiting
The Second Hospital of Anhui Medical University
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai GoBroad Cancer Hospital
Shanghai, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Hubei Cancer Hospital
Wuhan, China · Recruiting
Xiangyang Central Hospital
Xiangyang, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China · Recruiting
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.